CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkinson, C.
Right arrow Articles by McTiernan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkinson, C.
Right arrow Articles by McTiernan, A.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 868-874, May 2004
© 2004 American Association for Cancer Research

Short Communication

Effects of a Moderate Intensity Exercise Intervention on Estrogen Metabolism in Postmenopausal Women

Charlotte Atkinson1, Johanna W. Lampe1,2, Shelley S. Tworoger1,2, Cornelia M. Ulrich1,2, Deborah Bowen1, Melinda L. Irwin3, Robert S. Schwartz4, Bharat K. Rajan1,2, Yutaka Yasui1, John D. Potter1,2 and Anne McTiernan1,2

1 Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; 2 Department of Epidemiology, University of Washington, Seattle, Washington; 3 Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut; and 4 Department of Internal Medicine, Division of Geriatric Medicine, University of Colorado Health Sciences Center, Denver, Colorado

Requests for reprints: Anne McTiernan, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, P. O. Box 19024, Seattle, WA 98109. Phone: (206) 667-6196; Fax: (206) 667-7850. E-mail: amctiern{at}fhcrc.org


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Physical activity has been associated with reduced breast cancer risk, potentially via hormonal pathways, and high urinary excretion of 2-hydroxyestrone (2-OH E1) relative to 16{alpha}-hydroxyestrone (16{alpha}-OH E1) also has been associated with reduced breast cancer risk. Studies suggest that body composition and exercise can influence estrogen metabolism. We determined the effects of a 12-month moderate intensity aerobic exercise intervention on urinary 2-OH E1, 16{alpha}-OH E1, and their ratio in overweight and obese, previously sedentary, postmenopausal women, ages 50–75 years. Women were randomized to a 12-month exercise intervention (n = 87) or stretching control group (n = 86); 170 completed the study. Urinary 2- and 16{alpha}-OH E1 were measured in spot urines collected at baseline, 3, and 12 months. Body composition was measured at baseline and 12 months. Differences between exercisers and controls for excretion of estrogen metabolites were determined using general estimating equations. Further analyses assessed change in estrogen metabolites and their ratio by subgroups of change in body composition. Overall, there were no significant effects of the exercise intervention on 2-OH E1, 16{alpha}-OH E1, or their ratio (P > 0.05). There appeared to be an effect of change in intra-abdominal fat and adherence to the exercise intervention on change in the estrogen metabolites or their ratio. However, this did not reflect a potentially desirable change in estrogen metabolites associated with the exercise intervention. Thus, this 12-month moderate intensity exercise intervention did not significantly alter urinary excretion of 2-OH E1, 16{alpha}-OH E1, or their ratio in this population of women.

Key Words: Estrogen metabolite • exercise • postmenopausal women • randomized controlled trial


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
A large body of evidence implicates estrogens in the etiology of breast cancer (1) and it has been proposed that the determinants of circulating estrogen concentrations, and of estrogen metabolism, are potentially the primary causes of breast cancer (2). Physical activity has been associated with reduced risk of breast cancer (3), potentially via hormonal pathways. Following menopause, the primary source of estrogen is from the conversion of androgens to estrogens by adipose tissue aromatase (4, 5). Because exercise decreases body fat, especially abdominal fat, it has been proposed that an exercise intervention might reduce fat mass and subsequently alter the sex-hormone profile in postmenopausal women to one associated with lower risk for breast cancer (6, 7).

Estrogen metabolism in humans is mediated primarily by cytochrome P450 enzymes (8), and two of the major hydroxylated metabolites of estrone are 2-hydroxyestrone (2-OH E1) and 16{alpha}-hydroxyestrone (16{alpha}-OH E1) (9, 10). They are produced by competing pathways and have markedly different properties. 2-OH E1 is weakly estrogenic and data from studies in vitro and in animal models have suggested that it is anticarcinogenic (10). In contrast, 16{alpha}-OH E1 is more estrogenic, has been shown to form covalent bonds with estrogen receptors, and may be genotoxic (11–13). Therefore, it has been suggested that urinary excretion of these estrogen metabolites can be used as a risk marker for breast cancer (14, 15). In support of this hypothesis, some (16–19), but not all (20), retrospective and prospective studies have reported an increased risk of breast cancer associated with low urinary excretion of 2-OH E1 relative to 16{alpha}-OH E1.

Numerous factors have been suggested as possible modulators of estrogen metabolism in humans. For example, intakes of Brassica vegetables increase urinary excretion of 2-OH E1 relative to 16{alpha}-OH E1, potentially via induction of cytochrome P450 enzymes (21). In relation to body composition, obesity has been inversely associated with 2-hydroxylation (22, 23), and studies among athletes have reported positive associations between leanness and favoring the 2-hydroxylation pathway (24, 25), suggesting that both body composition and exercise (possibly via effects on body composition) can influence estrogen metabolism.

The Physical Activity for Total Health study was a randomized controlled clinical trial comparing the effect of a 12-month moderate intensity aerobic exercise intervention versus stretching control on the sex hormone profile in sedentary women (26). We report the effects of the exercise intervention on the urinary excretion of 2-OH E1, 16{alpha}-OH E1, and their ratio.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Participants
Full details of recruitment procedures and study participants have been published elsewhere (26, 27). Briefly, 173 women ages 50–75 years were recruited through mass mailings and media advertising. Eligible study participants had a body mass index (BMI) of 25–40 kg/m2 or BMI between 24 and 25 kg/m2 and percentage body fat >33%. They were postmenopausal [not experiencing menstrual periods for the previous 12 months, and follicle stimulating hormone (FSH) >30 mIU/ml for women aged 50–55 years] and sedentary (exercising at a level to produce sweating <60 min/week). Other major exclusion criteria included: use of hormone therapy, herbal hormones, tamoxifen, raloxifene, or oral contraceptives within the past 6 months; having medical conditions contraindicating moderate-to-vigorous intensity exercise; having a clinical diagnosis of diabetes or fasting blood glucose levels >140 mg/dl; currently using tobacco; and current moderate to high alcohol intake (more than two drinks per day). Full details of inclusion and exclusion criteria have been published elsewhere (26).

Data Collection
Demographic, medical history, reproductive history, and hormone-use history information were collected via a self-administered questionnaire at baseline. A food frequency questionnaire (FFQ) was used to assess dietary intake at baseline, 3, and 12 months (28). Height and weight were measured to the nearest 0.1 kg and 0.1 cm, respectively, at baseline, and after 3 and 12 months, using a balance-beam scale and stadiometer, respectively. Body fat percentage and lean tissue mass were assessed at baseline and after 12 months using a dual-energy X-ray absorptiometry (DEXA) whole-body scanner (Hologic QDR 1500, Hologic Inc., Waltham, MA). Abdominal fat, intra-abdominal fat (at the umbilicus, L4-L5 space; 125 kV and 8 mm thickness), and subcutaneous fat were measured at baseline and 12 months by computed tomography (General Electric model CT 9800 scanner, Waukesha, WI). Maximal oxygen consumption (VO2max) was measured at baseline and after 12 months; participants completed a maximal-graded treadmill test, with heart rate and oxygen uptake monitored by an automated metabolic cart (Medgraphics, St. Paul, MN). The test began at 3.0 mph and 0% grade. The speed or grade (2%) increments of the treadmill increased every 2 min. Treadmill tests were terminated when the participant reached volitional fatigue. Further details on all measurements have been published elsewhere (29).

Intervention
Women were randomly assigned to an exercise intervention group (87 women) or a stretching control group (86 women), stratified by BMI (<27.5 versus >=27.5 kg/m2). The exercise intervention consisted of at least 45 min of moderate-intensity exercise 5 days/week for 12 months. The aerobic exercise program was divided into two parts: a 3-month intensively monitored facility-based and a 9-month home-based exercise period. During the first 3 months, participants were required to attend three sessions/week at the exercise facility and to exercise 2 days/week at home. During the subsequent 9 months, participants were required to attend one session/week at the facility and to exercise 4 days/week on their own; participants were allowed to exercise additional days at the facility if they wished to do so. The training program began with a target of 40% of maximal heart rate for 16 min per session, and gradually increased to 60–70% of maximal heart rate for 45 min per session by week 8, at which point it was maintained for the duration of the study. Subjects primarily walked on a treadmill or rode a stationary bicycle at the training facility; women were encouraged to do 5–10 min of strength training to reduce risk of injury during the intervention. A variety of home exercises were suggested and encouraged, including walking, aerobics, and bicycling. Women were asked to keep daily logs of all sports or recreational activities they performed.

Participants in the stretching control group attended weekly 45-min stretching classes for 12 months, and were asked not to change other exercise habits during the study.

Both groups (exercisers and controls) were asked not to change their dietary patterns during the study.

Urine Samples, Estrogen Metabolites, and Creatinine
Study participants provided a fasting spot urine sample during clinic visits at baseline, and at months 3 and 12, and samples were stored at –70°C before analysis. Urine samples supplemented with vitamin C (62.5 mg per 25 ml of urine) were analyzed for 2-OH E1 and 16{alpha}-OH E1, and non-supplemented urine was used for creatinine analysis. Urinary estrogen metabolites were measured using the commercially available Estramet 2/16 enzyme immunoassay (EIA) kits (Immunacare Corporation, Bethlehem, PA). On receipt of the kits, all components were stored as recommended by the manufacturer. Urinary levels of 2-OH E1 and 16{alpha}-OH E1 were quantified as described previously (30, 31). All urine samples, standards, and controls were assayed in triplicate, and all samples from each subject were assayed in the same batch. Samples were batched such that, within each batch, the number of exercise and control subjects was approximately equal, the randomization dates of subjects were similar, and the sample order was random. Laboratory personnel were blinded with regard to subject identity. For quality control, a pool sample was created from ineligible subjects who were postmenopausal and not taking exogenous estrogens. Two blinded quality control samples and one laboratory quality control (not blinded) were included on each plate. Standard curves (using a log-linear scale) were sigmoidal and only the linear portion of the curve was used for quantitation. A coefficient of variation (CV) was calculated for each sample using data from triplicate measurements. Samples with a CV greater than 15% (primarily samples that were too concentrated or too dilute) were re-assayed using the appropriate dilution, or a mean of two out of the three wells was used, contingent on the CV of the two wells being less than 15%. If a sample needed to be re-assayed, all three time points for that woman were re-assayed on the same plate. On the basis of the blinded quality control sample, intra- and inter-assay CVs were 7.2% and 12.2%, respectively, for 2-OH E1, and 8.0% and 15.3%, respectively, for 16{alpha}-OH E1.

Urinary creatinine concentrations were measured using a kinetic modification of the Jaffe reaction using the Roche Reagent for Creatinine (Roche Diagnostic Systems, Nutley, NJ) on a Roche Cobas Mira Plus chemistry analyzer. The assay was linear to 20 mg/dl and the intra- and inter-assay CVs were 1.8% and 1.9%, respectively.

At baseline, 3 and 12 months, respectively, 2-OH E1 data were unavailable for 10, 8, and 9 women, and 16{alpha}-OH E1 data were unavailable for 6, 4, and 9 women. Reasons for data being unavailable included urine sample not collected, concentrations of estrogen metabolites that were not in the linear portion of the standard curve/unacceptable CVs that remained so even when duplicates or re-assays were considered, or creatinine data not available.

Statistical Analysis
All statistical analyses were performed using the SAS statistical package version 8.02 (SAS Institute, Cary, NC). The concentrations of 2-OH E1 and 16{alpha}-OH E1 were adjusted for creatinine excretion to account for variability in urinary output. Spearman correlation coefficients were calculated between baseline levels of the estrogen metabolites and baseline body composition measures, and between change in the estrogen metabolites and change in body composition measures. Brassica vegetable intakes have been associated with levels of 2-OH E1 and 16{alpha}-OH E1 (21); therefore, we assessed differences between exercisers and stretchers for mean change (baseline to 12 months) in vegetable and fiber intakes using unpaired t tests. We also investigated differences between treatment groups in total energy intakes at each time point, and change over time, using unpaired t tests. Differences between exercisers and stretchers for changes in estrogen metabolites and their ratio were tested using linear regression via general estimating equations, and all analyses were based on assigned treatment at the time of randomization (i.e., intent-to-treat). Estrogen metabolite data were log transformed (ln) to normalize the data for the general estimating equations analyses. In a secondary analysis, we explored between-group differences for changes in estrogen metabolites from baseline to 12 months, stratifying by change in weight [gained >0.5 kg (reference group), gained or lost <=0.5 kg, lost 0.5–3 kg, lost >3 kg]; change in percentage body fat [gained >0.5 % (reference group), gained or lost <=0.5%, lost 0.5–2%, lost >2%]; change in intra-abdominal fat [gained >15 cm2 (reference group), gained 0–15 cm2, lost up to 15 cm2, lost >15 cm2]; change in lean body mass [lost >700 g (reference group), lost up to 700 g, gained 0–700 g, or gained >700 g]; and change in VO2max [decrease or no change (reference group), 1–10% increase, or >10% increase]. In addition, for women in the exercise group, duration of exercise [minutes per week of sports or recreational activities of at least three metabolic equivalents, METs (32)] was calculated, and mean change in the estrogen metabolites was compared across tertiles of adherence (<130 min/week; 130–190 min/week; >190 min/week).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Selected baseline characteristics did not differ significantly between the exercise and control groups (Table 1). There were no associations between baseline levels of the estrogen metabolites (2-OH E1, 16{alpha}-OH E1, and their ratio) and BMI, percentage body fat, lean body mass (g), abdominal fat (cm2), and subcutaneous fat (cm2) (P > 0.05). Correlations between baseline intra-abdominal fat (cm2) and 2-OH E1 and 16{alpha}-OH E1 were weak (r = –0.17, P = 0.03; and r = –0.20, P = 0.01, respectively); there was no correlation between baseline intra-abdominal fat and the 2-OH E1:16{alpha}-OH E1 ratio (r = –0.02, P = 0.75).


View this table:
[in this window]
[in a new window]
  		Table 1. Baseline characteristics of randomized participants

 
Of the 87 women randomized into the exercise intervention group: 81 (93%) were considered adherent (i.e., met >=80% of the goal of 225 min/week of moderate-to-vigorous intensity exercise); 87 (100%) returned for the 3-month clinic visit; 84 (97%) returned for the 12-month clinic visit. On average, the women participated in 199 min of moderate-to-vigorous intensity exercise over 4 days/week. Of the 86 women randomized into the stretching control group, all returned for the 3- and 12-month clinic visits. Six controls (7%) increased their exercise to 225 min/week, based on a self-reported questionnaire.

From baseline to 12 months, women in the exercise group lost an average of 1.29 kg (SD 3.8 kg), whereas women in the stretching control group gained an average of 0.1 kg (SD 3.0 kg) (P < 0.01). Further details regarding changes in body composition have been reported elsewhere (29). There were no significant differences between exercisers and stretchers for changes in dietary intakes of vegetables and fiber from baseline to 3 months, or from baseline to 12 months (P > 0.1; data not shown). In addition, there were no statistically significant differences between exercisers and stretchers in total energy intake at baseline, 3, or 12 months, or in change from baseline to 3 months or baseline to 12 months (P > 0.1; data not shown).

There were weak correlations between change in lean tissue mass and change in 2-OH E1 (r = 0.16, P = 0.05) and between change in lean tissue mass and change in 2-OH E1:16{alpha}-OH E1 ratio (r = 0.17, P = 0.04). When stratified by intervention group, there were weak correlations between change in lean tissue mass and change in 2-OH E1 among exercisers (r = 0.25, P = 0.03), and between change in intra-abdominal fat and change in 2-OH E1 among controls (r = –0.23, P = 0.05). There were no other correlations between changes in body composition measures and changes in the estrogen metabolites and their ratio (P > 0.05).

Overall, there were no differences between the groups for changes in 2-OH E1, 16{alpha}-OH E1, or their ratio (Table 2). When stratified by change in body-composition measures, change in intra-abdominal fat appeared to modify the effect of exercise on changes in 2-OH E1 and the 2-OH E1:16{alpha}-OH E1 ratio (Table 3); when compared with the reference group (women who gained >15 cm2), differences between treatment groups were statistically significant for the changes in 2-OH E1 and the 2OH E1:16{alpha}-OH E1 ratio among women who lost up to or greater than 15 cm2. When stratified by changes in weight, lean body mass, percentage body fat, and VO2max, there were no statistically significant differences between treatment groups (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2. Geometric mean (95% confidence interval) 2-OH E1, 16{alpha}-OH E1, and their ratio at baseline, and at months 3 and 12 for women in the exercise intervention and control groups*

 

View this table:
[in this window]
[in a new window]
  		Table 3. Geometric mean (95% confidence interval) 2-OH E1, 16{alpha}-OH E1, and their ratio at baseline and at 12 months for women in the exercise and control groups, stratified by change in intra-abdominal fat*

 
Among women in the exercise group, there were statistically significant differences between the low (reference) and intermediate adherence groups for the change in 2-OH E1:16{alpha}-OH E1 ratio from baseline to 3 months and from baseline to 12 months. However, differences between the low and high adherence groups, and trend tests on the adherence categories, were not statistically significant (Table 4).


View this table:
[in this window]
[in a new window]
  		Table 4. Geometric mean (95% confidence interval) 2-OH E1, 16{alpha}-OH E1, and their ratio at baseline, and at months 3 and 12 in exercisers by minutes of exercise per week*

 
One woman in the exercise group had large changes in 2-OH E1 and 16{alpha}-OH E1 from baseline to 12 months (–56.9 ng/mg creatinine and –41.3 ng/mg creatinine, respectively); excluding her data from the analyses did not substantially change the results.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
To our knowledge, this is the first study to have investigated the effects of a 12-month exercise intervention on the urinary excretion of 2-OH E1, 16{alpha}-OH E1, and their ratio, in a population of previously sedentary and overweight postmenopausal women. Overall, we did not see a significant effect of the intervention on 2-OH E1, 16{alpha}-OH E1, or their ratio.

Data from a number of cross-sectional studies have suggested that an individual's body fat content might influence estrogen metabolism. For example, in athletes, the extent of 2-hydroxylation was inversely associated with adiposity (24, 25, 33), and in a comparison of obese and anorexic girls, higher body weight was associated with a reduction in 2-hydroxylation and an increase in 16{alpha}-hydroxylation (22). In a study of obese and normal weight individuals, obesity also was associated with significantly lower 2-hydroxylation, but there was no effect on 16{alpha}-hydroxylation (23). In contrast with these earlier cross-sectional associations, we did not observe a significant association of BMI, percentage body fat, lean body mass, abdominal fat, or subcutaneous fat with baseline levels of 2-OH E1, 16{alpha}-OH E1, or their ratio. However, we selected only overweight or obese women for this study; therefore, the homogeneity of the study population may have limited our ability to detect potential associations. There were weak inverse associations between baseline intra-abdominal body fat and 2-OH E1 and 16{alpha}-OH E1. Reasons for this are unclear, but might be due to low levels of aromatase activity in intra-abdominal body fat (34), resulting in reduced levels of estrogens available for conversion to 2-OH E1 and 16{alpha}-OH E1.

Our findings are consistent with a study of premenopausal women assigned to an intensive 6-month dietary and lifestyle intervention, which included goals to increase physical activity and to lose weight (35). In that study, the change in 2-OH E1:16{alpha}-OH E1 ratio was not significantly different from the change among women assigned to the control group. Change in body fat was not measured and the authors suggested that, even though their study participants lost weight, it may not have been sufficient to bring about the depletion of fat stores necessary for increasing 2-hydroxylation (35). Similarly, in our study, despite the fact that women in the exercise group lost significantly more weight than the women in the control group (29), the reduction in weight was modest. When we stratified our analyses according to weight change, differences between treatment groups remained non-significant, further suggesting that the extent of weight loss in this study may not have been sufficient to have a substantial effect on the estrogen metabolites.

We observed weak positive correlations between change in lean body mass and change in 2-OH E1, which is partially in agreement with studies in athletes and obese individuals, in which adiposity was negatively associated with 2-hydroxylation (22–25, 33). However, stratification by change in lean body mass in the longitudinal (general estimating equations) analysis did not modify the effect of the intervention on change in the estrogen metabolites.

There appeared to be an effect of change in intra-abdominal fat and adherence to the intervention on the change in the estrogen metabolites and their ratio, but it did not, overall, reflect a potentially desirable change in the estrogen metabolites associated with the exercise intervention.

The intensity of physical activity has been positively associated with serum levels of 2-OH E1 in premenopausal women in one (36), but not another (25), study. In our study, the intensity of exercise undertaken by the participants was moderate; therefore, we cannot exclude the possibility that a more vigorous intensity intervention might have a significant effect on estrogen metabolism, potentially via greater changes in weight and/or body composition than were seen in the present study. Alternatively, it is possible that the effects of exercise on these estrogen metabolites might differ between premenopausal and postmenopausal women.

Another factor that could have contributed to the essentially null findings in this study is the timing of the intervention in relation to life events. It is possible that exercise during adolescence or early adulthood, when breast tissue is developing, may be more important in terms of providing protection against breast cancer. Some (37–39), although not all (40–42), studies have shown protective effects of exercise during adolescence or early adulthood on subsequent risk of breast cancer. It would be interesting to determine the effects of an exercise intervention on estrogen metabolism in adolescents or young adults.

To our knowledge, this is one of the largest and longest exercise intervention trials among postmenopausal women to date; however, despite this, a potential limitation of this study is the sample size. A small number of women (7%) in the control group increased their level of physical activity to 225 min/week, but this is unlikely to have influenced the findings. Major strengths of this study included the excellent adherence to the exercise program, the low dropout rate, and the randomized controlled study design.

In conclusion, this 12-month moderate intensity exercise intervention did not significantly alter the urinary excretion of 2-OH E1, 16{alpha}-OH E1, or their ratio in this population of postmenopausal women.


   Acknowledgments
 
We are indebted to the participants and study staff in the Physical Activity for Total Health Study for their dedication.


   Footnotes
 
Grant support: National Cancer Institute (RO1 CA69334) and National Institutes of Environmental Health Sciences Training Grant (T32EF07262) (S.S. Tworoger).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/13/03; revised 12/19/03; accepted 1/ 5/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36–47.[Free Full Text]
  2. Kuller LH, Matthews KA, Meilahn EN. Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis. J Steroid Biochem Mol Biol 2000;74:297–309.[CrossRef][Medline]
  3. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132:3456S–64S.[Abstract/Free Full Text]
  4. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207–14.[Medline]
  5. Siiteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW. The serum transport of steroid hormones. Recent Prog Horm Res 1982;38:457–510.
  6. Gammon MD, John EM, Britton JA. Recreational and occupational physical activities and risk of breast cancer. J Natl Cancer Inst 1998;90:100–17.[Abstract/Free Full Text]
  7. McTiernan A, Ulrich C, Slate S, Potter J. Physical activity and cancer etiology: associations and mechanisms. Cancer Causes Control 1998;9:487–509.[CrossRef][Medline]
  8. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1–27.[Abstract/Free Full Text]
  9. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16{alpha}-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984;20:1077–81.[CrossRef][Medline]
  10. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the ‘good’ estrogen. J Endocrinol 1996;150:S259–65.[Abstract]
  11. Fishman J, Martucci C. Biological properties of 16{alpha}-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 1980;51:611–5.[Abstract]
  12. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16{alpha}-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988;85:7831–5.[Abstract/Free Full Text]
  13. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16{alpha}-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634–8.[Abstract/Free Full Text]
  14. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982;79:3047–51.[Abstract/Free Full Text]
  15. Bradlow HL, Hershcopf RE, Fishman JF. Oestradiol 16{alpha}-hydroxylase: a risk marker for breast cancer. Cancer Surv 1986;5:573–83.[Medline]
  16. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16{alpha}-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635–640.[CrossRef][Medline]
  17. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomark Prev 1997;6:505–9.[Abstract]
  18. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250–5.[Medline]
  19. Zheng W, Dunning L, Jin F, Holtzman J. Correspondence re: Kabat GC et al., Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomark Prev 1998;7:85–6.[Medline]
  20. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16{alpha}-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067–72.[Abstract/Free Full Text]
  21. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomark Prev 2000;9:773–9.[Abstract/Free Full Text]
  22. Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab 1975;41:989–91.[Abstract]
  23. Schneider J, Bradlow HL, Strain G, Levin J, Anderson K, Fishman J. Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. J Clin Endocrinol Metab 1983;56:973–8.[Abstract]
  24. Frisch RE, Snow RC, Johnson LA, Gerard B, Barbieri R, Rosen B. Magnetic resonance imaging of overall and regional body fat, estrogen metabolism, and ovulation of athletes compared to controls. J Clin Endocrinol Metab 1993;77:471–7.[Abstract]
  25. Snow RC, Barbieri RL, Frisch RE. Estrogen 2-hydroxylase oxidation and menstrual function among elite oarswomen. J Clin Endocrinol Metab 1989;69:369–76.[Abstract]
  26. McTiernan A, Ulrich CM, Yancey D, et al. The Physical Activity for Total Health (PATH) Study: rationale and design. Med Sci Sports Exerc 1999;31:1307–12.[Medline]
  27. Tworoger SS, Yasui Y, Ulrich CM, et al. Mailing strategies and recruitment into an intervention trial of the exercise effect on breast cancer biomarkers. Cancer Epidemiol Biomark Prev 2002;11:73–7.[Abstract/Free Full Text]
  28. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178–87.[CrossRef][Medline]
  29. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003;289:323–30.[Abstract/Free Full Text]
  30. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998;63:406–13.[CrossRef][Medline]
  31. Atkinson C, Skor HE, Fitzgibbons ED, et al. Urinary equol excretion in relation to 2-hydroxyestrone and 16a-hydroxyestrone concentrations: an observational study of young to middle-aged women. J Steroid Biochem Mol Biol 2003;86:71–7.[Medline]
  32. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32:S498–504.[Medline]
  33. Frisch RE, Snow R, Gerard EL, et al. Magnetic resonance imaging of body fat of athletes compared with controls, and the oxidative metabolism of estradiol. Metabolism 1992;41:191–3.[Medline]
  34. Killinger DW, Perel E, Daniilescu D, Kharlip L, Lindsay WR. The relationship between aromatase activity and body fat distribution. Steroids 1987;50:61–72.[CrossRef][Medline]
  35. Pasagian-Macaulay A, Meilahn EN, Bradlow HL, et al. Urinary markers of estrogen metabolism 2- and 16{alpha}-hydroxylation in premenopausal women. Steroids 1996;61:461–7.[CrossRef][Medline]
  36. Russell JB, Mitchell D, Musey PI, Collins DC. The relationship of exercise to anovulatory cycles in female athletes: hormonal and physical characteristics. Obstet Gynecol 1984;63:452–6.[Abstract/Free Full Text]
  37. Marcus PM, Newman B, Moorman PG, et al. Physical activity at age 12 and adult breast cancer risk (United States). Cancer Causes Control 1999;10:293–302.[CrossRef][Medline]
  38. Mittendorf R, Longnecker MP, Newcomb PA, et al. Strenuous physical activity in young adulthood and risk of breast cancer (United States). Cancer Causes Control 1995;6:347–53.[CrossRef][Medline]
  39. Hu YH, Nagata C, Shimizu H, Kaneda N, Kashiki Y. Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat 1997;43:65–72.[CrossRef][Medline]
  40. Friedenreich CM, Courneya KS, Bryant HE. Influence of physical activity in different age and life periods on the risk of breast cancer. Epidemiology 2001;12:604–12.[CrossRef][Medline]
  41. McTiernan A, Stanford JL, Weiss NS, Daling JR, Voigt LF. Occurrence of breast cancer in relation to recreational exercise in women age 50–64 years. Epidemiology 1996;7:598–604.[Medline]
  42. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA 2003;290:1331–6.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. H. Schmitz, M. Warren, A. G. Rundle, N. I. Williams, M. D. Gross, and M. S. Kurzer
Exercise Effect on Oxidative Stress Is Independent of Change in Estrogen Metabolism
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 220 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. L. Campbell, K. C. Westerlind, V. J. Harber, G. J. Bell, J. R. Mackey, and K. S. Courneya
Effects of Aerobic Exercise Training on Estrogen Metabolism in Premenopausal Women: A Randomized Controlled Trial
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 731 - 739.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
D. D. Baird, D. B. Dunson, M. C. Hill, D. Cousins, and J. M. Schectman
Association of Physical Activity with Development of Uterine Leiomyoma
Am. J. Epidemiol., January 15, 2007; 165(2): 157 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
K. L. Campbell and A. McTiernan
Exercise and Biomarkers for Cancer Prevention Studies
J. Nutr., January 1, 2007; 137(1): 161S - 169S.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkinson, C.
Right arrow Articles by McTiernan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkinson, C.
Right arrow Articles by McTiernan, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation